




AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. – 22. (Canceled)

23. (Previously presented). A compound of the following formula I, or a pharmaceutically



acceptable salt thereof[.],

(I)

wherein:

R^1 and R^2 are each independently selected from the group consisting of H, F, Cl, Br, I, NO_2 , CF_3 , CN, OCF_3 , OH, $\text{C}_1\text{-C}_4$ alkoxy-, $\text{C}_1\text{-C}_4$ alkylcarbonyl-, $\text{C}_1\text{-C}_6$ alkyl, hydroxy $\text{C}_1\text{-C}_4$ alkyl-, $\text{C}_3\text{-C}_6$ alkenyl, $\text{C}_3\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl($\text{C}_0\text{-C}_4$ alkyl)-, $\text{H}_2\text{N}(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^6\text{HN}(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^6\text{R}^7\text{N}(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^7\text{S}(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^7\text{S}(\text{O})(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^7\text{SO}_2(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^6\text{NSO}_2(\text{C}_0\text{-C}_4)$ alkyl-, HSO_3 , $\text{HO}_2\text{C}(\text{C}_0\text{-C}_4)$ alkyl-, $\text{R}^6\text{O}_2\text{C}(\text{C}_0\text{-C}_4)$ alkyl-, and $\text{R}^6\text{R}^7\text{NCO}(\text{C}_0\text{-C}_4)$ alkyl-,

or R^1 and R^2 , when on adjacent carbon atoms, and when taken together are methylenedioxy or ethylenedioxy;

R^5 is independently selected from H, F, Cl, Br, I, NO_2 , CN, CF_3 , OCF_3 , OH, $\text{C}_1\text{-C}_4$ alkoxy-, hydroxy $\text{C}_1\text{-C}_4$ alkyl-, $\text{C}_1\text{-C}_4$ alkylcarbonyl-, CO_2H , CO_2R^6 , CONR^6R^7 , NHR^6 , and NR^6R^7 ;

R^6 is selected from H, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_3\text{-C}_6$ alkenyl, $\text{C}_3\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl($\text{C}_0\text{-C}_4$ alkyl)-, aryl($\text{C}_0\text{-C}_4$ alkyl)-, and heterocyclic ($\text{C}_0\text{-C}_4$ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy C₀-C₄ alkyl, oxo, F, Cl, Br, CF₃, NO₂, CN, OCF₃, NH₂, NHR⁷, NR⁷R⁸, SR⁷, S(O)R⁷, SO₂R⁷, SO₂NR⁷R⁸, CO₂H, CO₂R⁷, and CONR⁷R⁸;

R⁷ and R⁸ are each independently selected from H, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, C₁-C₆ alkylcarbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkyl)carbonyl, C₁-C₆ alkoxy carbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkoxy)carbonyl, aryl(C₁-C₅ alkoxy)carbonyl, arylsulfonyl, aryl(C₀-C₄ alkyl)-, heterocyclic(C₁-C₅ alkoxy)carbonyl, heterocyclic sulfonyl and heterocyclic (C₀-C₄ alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

or R⁶ and R⁷, or R⁶ and R⁸, or R⁷ and R⁸, when both substituents are on the same nitrogen atom, do or do not form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidiny, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl, said heterocycle is unsubstituted or substituted with 0-3 groups selected from oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl(C₀-C₄ alkyl)-, C₁-C₆ alkylcarbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkyl)carbonyl, C₁-C₆ alkoxy carbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkoxy)carbonyl, aryl(C₀-C₅ alkyl), heterocyclic(C₀-C₅ alkyl), aryl(C₁-C₅ alkoxy)carbonyl, heterocyclic(C₁-C₅ alkoxy)carbonyl, C₁-C₆ alkylsulfonyl, arylsulfonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

K is selected from -C(=O)- and -CHR⁹-;

L is selected from -C(=O), -CHR⁹-, -CR¹⁰R¹¹-, -CR¹⁰R¹¹-(C=O), -HR¹⁵C-CHR¹⁶-, and -R¹⁵C=CR¹⁶;

R⁹ is selected from H, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, aryl(C₀-C₄ alkyl)-, and heterocyclic(C₀-C₄ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, and NO₂;

R¹⁰ is selected from H, F, Cl, Br, C₁-C₆ alkoxy, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, aryl(C₀-C₄ alkyl)-, and heterocyclic(C₀-C₄ alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

R¹¹ is selected from H, F, Cl, Br, OMe, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, aryl(C₀-C₄ alkyl)-, and heterocyclic(C₀-C₄ alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

or R¹⁰ and R¹¹, when on the same carbon atom, do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy C₀-C₄ alkyl, oxo, F, Cl, Br, CF₃, and NO₂;

R¹² is selected from H, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, monocyclic or bicyclic 5-10 membered heterocyclic(C₀-C₄ alkyl)-, and -CZ¹Z²Z³, provided -CZ¹Z²Z³ is not C₁-C₈ alkyl,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R¹⁴;

Z¹ is selected from C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₄ alkoxy C₁-C₄ alkyl, aryl(C₀-C₄ alkyl)-, and 4-10 membered heterocyclic (C₀-C₄ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R¹⁴;

Z² is selected from C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₄ alkoxy C₁-C₄ alkyl, C₁-C₆ NR¹⁷R¹⁸, aryl(C₀-C₄ alkyl)-, and 4-10 membered heterocyclic (C₀-C₄ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R¹⁴;

Z³ is selected from C₁-C₈ alkyl, R¹⁴(C₂-C₄ alkyl)-, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₄ alkoxy C₁-C₄ alkyl, aryl(C₀-C₄ alkyl)-, 4-10 membered heterocyclic (C₀-C₄ alkyl)-, R¹⁷O=C(C₀-C₄ alkyl)-, R¹⁷OO=C(C₀-C₄ alkyl)-, and R¹⁷R¹⁸NO=C(C₀-C₄ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R¹⁴;

or Z¹ and Z², when on the same carbon atom, may form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring system, said carbocyclic or heterocyclic ring may be substituted with 0-2 substituents independently selected from R¹⁴[.];

R¹³ is selected from H, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylsulfonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkyl)carbonyl, C₁-C₆ alkoxycarbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkoxy)carbonyl, aryl(C₀-C₄ alkyl)-, aryl(C₁-C₅ alkoxy)carbonyl, arylsulfonyl, heterocyclic(C₀-C₄ alkyl), heterocyclic(C₁-C₅ alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

R¹⁴ is selected from H, C₁-C₁₀ alkyl, NO₂, CF₃, CN, F, Cl, Br, C₁-C₁₀ alkylcarbonyl, haloalkyl, haloalkoxy, OH, NR⁶R⁷(C₀-C₄ alkyl)-, R⁶C(=O)O(C₀-C₄ alkyl)-, R⁶OC(=O)O(C₀-C₄ alkyl)-, R⁶O(C₀-C₄ alkyl), R⁶R⁷NC(=O)O(C₀-C₄ alkyl)-, R⁶R⁷NC(=O)(C₀-C₄ alkyl)-, R⁶O(CR¹⁰R¹¹)₂₋₆R⁶NC(=O)(C₀-C₄ alkyl)-, R⁶R⁷N(CR¹⁰R¹¹)₂₋₆R⁶NC(=O)(C₀-C₄ alkyl)-, R⁶O₂C(CH₂)₁₋₄O(C₀-C₄ alkyl)-, R⁶OOC(C₁-C₄ alkoxy)-, R⁶OOC(C₀-C₄ alkyl)-, R⁶C(=O)(C₀-C₄ alkyl)-, R⁶C(=O)NR⁷(C₀-C₄ alkyl)-, R⁶OC(=O)NR⁷(C₀-C₄ alkyl)-, R⁶OC(=NCN)NR⁷(C₀-C₄ alkyl)-, R⁶R⁷NC(=O)NR⁸(C₀-C₄ alkyl)-, R⁶OC(=NC)NR⁷(C₀-C₄ alkyl)-, R⁶(CR¹⁰R¹¹)₁₋₄NR⁷C=O-, R⁶O(CR¹⁰R¹¹)₁₋₄O=CR⁷N-, NR⁶R⁷(CR¹⁰R¹¹)₁₋₄C=OR⁷N-, R⁶O(CR¹⁰R¹¹)₂₋₄R⁷N-, R⁶O₂C(CR¹⁰R¹¹)₁₋₄R⁷N-, R⁶R⁷N(CR¹⁰R¹¹)₂₋₄R⁷N-, R⁶R⁷NC(=NCN)NR⁷(C₀-C₄ alkyl)-, R⁶R⁷NC(=C(H)(NO₂))NR⁷(C₀-C₄ alkyl)-, R⁷R⁸N C(=NR⁷)NR⁷(C₀-C₄ alkyl)-, R⁶R⁷N SO₂NR⁸(C₀-C₄ alkyl)-, R⁶SO₂NR⁷(C₀-C₄

alkyl)-, $R^6R^7N(C_1-C_4)CO-$, $R^6R^7N(C_2-C_6\text{ alkyl})O-$, $R^6CO(CR^{10}R^{11})_{0-2}R^7N(O_2)S(C_0-C_4\text{ alkyl})$, $R^6(O_2)SR^7NC(=O)(C_0-C_4\text{ alkyl})-$, $R^6S(C_0-C_4\text{ alkyl})-$, $R^6S(=O)(C_0-C_4\text{ alkyl})-$, $R^6SO_2(C_0-C_4\text{ alkyl})-$, $SO_2NR^6R^7$, $SiMe_3$, $R^6R^7N(C_2-C_4\text{ alkyl})-$, $R^6R^7N(C_2-C_4\text{ alkoxy})-$, HSO_3 , $HONH-$, R^6ONH- , $R^8R^7NNR^6-$, $HO(COR^6)N-$, $HO(R^6O_2C)N$, C_2-C_6 alkenyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylmethyl, aryl($C_0-C_4\text{ alkyl}$)-, heteroaryl($C_0-C_4\text{ alkyl}$)-, aryl($C_0-C_4\text{ alkyl}$)O-, and heteroaryl($C_0-C_4\text{ alkyl}$)O-,

wherein said aryl groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3 , and NO_2 ;


R^{15} is selected from H, halo, cyano, C_1-C_8 alkyl, C_3-C_6 alkenyl, and C_3-C_{10} cycloalkyl($C_0-C_4\text{ alkyl}$)-, aryl($C_0-C_4\text{ alkyl}$)-, and heterocyclic($C_0-C_4\text{ alkyl}$)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14} ; and

R^{16} is selected from H, halo, cyano, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl($C_0-C_4\text{ alkyl}$)-, aryl($C_0-C_4\text{ alkyl}$)-, and heterocyclic($C_0-C_4\text{ alkyl}$)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14} ;

or when R^{15} and R^{16} are on adjacent carbon atoms, or when R^{15} and R^{16} are oriented on the same side of the double bond, as depicted in the following structure (III)



(III),

R^{15} and R^{16} do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic aromatic or nonaromatic ring system, or a 3-7 membered heterocyclic aromatic or nonaromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3 , and NO_2 ;

R^{17} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl($C_0-C_4\text{ alkyl}$)-, C_1-C_6 alkylcarbonyl, C_1-C_6 alkylsulfonyl, C_3-C_7 cycloalkyl($C_0-C_5\text{ alkyl}$)carbonyl, C_1-C_6 alkoxy carbonyl, C_3-C_7 cycloalkyl($C_0-C_5\text{ alkoxy}$)carbonyl, hydroxy($C_2-C_4\text{ alkyl}$)-, C_1-C_3 alkoxy($C_2-C_4\text{ alkyl}$)-, ($C_0-C_4\text{ alkyl}$) ($C_0-C_4\text{ alkyl}$) amino($C_2-C_4\text{ alkyl}$)-, aryl($C_0-C_4\text{ alkyl}$)-, aryl($C_1-C_5\text{ alkoxy}$)carbonyl ,

arylsulfonyl, heterocyclic(C₀-C₄ alkyl), heterocyclic(C₁-C₅ alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxy C₁-C₄ alkyl, oxo, F, Cl, Br, CF₃, CN, and NO₂; and

R¹⁸ is selected from H, C₁-C₈ alkyl, C₃-C₆ alkenyl, C₃-C₁₀ cycloalkyl(C₀-C₄ alkyl)-, aryl(C₀-C₄ alkyl)-, and heterocyclic(C₀-C₄ alkyl),


wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, F, Cl, Br, CF₃, CN, and NO₂;

or R¹⁷ and R¹⁸, when both are on the same nitrogen atom, may form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidiny, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl,

said heterocycle may be substituted with 0-3 groups selected from oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl(C₀-C₄ alkyl)-, C₁-C₆ alkylcarbonyl, (C₁-C₆ alkylcarbonyl)(C₀-C₄alkyl)amino-, C₃-C₇ cycloalkyl(C₀-C₅ alkyl)carbonyl, C₁-C₆ alkoxy carbonyl, C₃-C₇ cycloalkyl(C₀-C₅ alkoxy)carbonyl, aryl(C₀-C₅ alkyl), heterocyclic(C₀-C₅ alkyl), aryl(C₁-C₅ alkoxy)carbonyl, heterocyclic(C₁-C₅ alkoxy)carbonyl, C₁-C₆ alkylsulfonyl arylsulfonyl and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from CH₃-, alkoxy, F, Cl, Br, CF₃, CN, and NO₂.

24. (Previously presented). A compound or pharmaceutically acceptable salt thereof of Claim 23 having the formula,



wherein

R¹ and R² are each independently selected from the group consisting of H, F, Cl, Br, I, NO₂, CF₃, CN, OCF₃, OH, C₁-C₄alkoxy-, and C₁-C₄alkyl-;

R^5 is selected from the group consisting of H, F, Cl, Br, I, NO_2 , CN, CF_3 , OCF_3 , OH, C_1 - C_4 alkoxy, and CO_2H ; and

R^7 is selected from hydrogen and C_1 - C_8 alkyl.

25. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 24 wherein

R^5 is H;

R^1 is selected from the group consisting of OCF_3 and C_1 - C_4 alkoxy;

R^2 is H; and


R^{13} is hydrogen.

26. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is $C(=O)$; and

L is $C(=O)$.

27. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 26 having the formula,



wherein R^{12} is $-CZ^1Z^2Z^3$.

28. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 27 wherein:

R^7 is hydrogen; and

R^1 is methoxy.

29. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 28 wherein Z^1 and Z^2 are independently selected from C_1 - C_8 alkyl.

30. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is CHR⁹.

31. (Previously presented). A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is CHR⁹ and

L is C(=O).

32. (Previously presented). A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is -CR¹⁰R¹¹-(C=O).

33. (Previously presented). A compound or pharmaceutically acceptable salt thereof, wherein said compound is selected from:

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(phenylmethyl)ethanediamide;

N-[1,1-Bis(hydroxymethyl)propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(2-Hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine 1,1-dimethylethyl ester;

N-(2-Hydroxy-1,1-dimethylpentyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Hydroxy-1,1-dimethylethyl)amino]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(1,1-Diethyl-2-propynyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1-(Hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(4-Fluorophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]- α -methyltyrosine methyl ester;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]- α -methyltryptophan methyl ester;

N-[1,1-Bis(hydroxymethyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;
 N-(1,1-Dimethyl-3-oxobutyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1-methyl-1-phenylethyl)ethanediamide;
 N-(2-Hydroxy-1,2-dimethyl-1-phenylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine methyl ester;
 -[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]cyclopropanecarboxylic acid methyl ester;
 N-(1-Ethynylcyclohexyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 (R)-N-[1-(Hydroxymethyl)-1-methylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;
 N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine;
 N-[1,1-Dimethyl-2-oxo-2-(1-piperidinyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-(4-morpholinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 4-[2-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methyl-1-oxopropyl]-1-piperazinecarboxylic acid ethyl ester;
 N-[2-[3-(Acetylmethylamino)-1-pyrrolidinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-[methyl[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-oxo-2-(propylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-[[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;
 N-[1,1-Dimethyl-2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(Acetyl amino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-1-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[tetrahydro-2-furanyl)methyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Methoxyethyl)amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[4-(2-Methoxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide; and

N-[1,1-Dimethyl-2-oxo-2-(2-pyridinylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide.

34. (Previously presented). A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant or vehicle and at least one compound of claim 23, or a pharmaceutically acceptable salt thereof, in an amount effective therefor.

35. (Withdrawn). A method for the treatment of an IMPDH-associated disorder, comprising the step of administering to a subject in need thereof an amount effective therefor of at least one compound of claim 23 or a pharmaceutically acceptable salt thereof.

36. (Withdrawn). The method of claim 35, wherein said IMPDH-associated disorder is selected from an autoimmune disorder, an inflammatory disorder, a cancer or tumor disorder, a DNA or RNA viral replication disease, and allograft rejection.

37. (Withdrawn). The method of claim 36, wherein said IMPDH-associated disorder is selected from transplant rejection, rheumatoid arthritis, inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex type I, and herpes simplex type II.

38. (Withdrawn). The method of claim 37, wherein said compound of claim 23, or a pharmaceutically acceptable salt thereof, is administered with one or more of: an immunosuppressant, an anti-cancer agent, an anti-viral agent, an anti-inflammatory agent, an anti-fungal agent, an antibiotic, an anti-vascular hyperproliferation compound, or an IMPDH inhibitor other than a compound of claim 23 or a pharmaceutically acceptable salt thereof.

39. (Withdrawn). The method of claim 38 wherein said compound of claim 23 or a pharmaceutically acceptable salt thereof, is administered with one or more of: another IMPDH inhibitor; a cyclosporin; CTLA4-Ig; an antibody selected from anti-ICAM-3, anti-IL-2 receptor (Anti-Tac), anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, and monoclonal antibody OKT3; an agent blocking the interaction between CD40 and CD154; a fusion protein constructed from CD40 and/or CD154/gp39; an inhibitor of NF-kappa B function; a non-steroidal antiinflammatory drug (NSAID); a gold compound; an antiviral agent; an antiproliferative ; a cytotoxic drug; an TNF- α inhibitor; an anti-TNF antibody; a soluble TNF receptor; and rapamycin (sirolimus or Rapamune); or derivatives thereof.